Toronto, Jan. 13, 2026 — Cardiol Therapeutics Inc. announced that it has surpassed the 50% patient enrollment milestone in MAVERIC, its pivotal Phase III, randomized, double-blind, placebo-controlled clinical trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis. The achievement marks a critical execution milestone for the late-stage biopharmaceutical company and reflects strong investigator engagement across more than 15 leading cardiovascular centers in the United States, with additional sites in Europe and Canada actively coming online to support continued enrollment momentum.
Science Significance
From a scientific perspective, MAVERIC represents one of the most rigorous late-stage evaluations of an oral, non-immunosuppressive anti-inflammatory therapy in recurrent pericarditi. CardiolRx™ is designed to modulate inflammasome pathway activation, a key intracellular mechanism implicated in inflammation and fibrosis in cardiac disease. The Phase III trial builds on positive results from the earlier Phase II MAvERIC-Pilot study, which demonstrated rapid and sustained reductions in pericarditis pain, inflammatory markers, and recurrence frequency, even in patients with a high baseline disease burden. The MAVERIC study’s primary endpoint—freedom from recurrent pericarditis episodes after six months of treatment—is clinically meaningful and directly aligned with patient outcomes.
Regulatory Significance
The 50% enrollment milestone is highly significant from a regulatory and GCP compliance standpoint. MAVERIC is designed as a registrational Phase III trial, intended to support future regulatory submissions in major markets. The study incorporates international, multicenter oversight, a blinded and placebo-controlled design, and clearly defined primary and secondary endpoints, all of which align with regulatory expectations for late-stage cardiovascular drug development. Importantly, CardiolRx™ has already received Orphan Drug Designation from the U.S. Food and Drug Administration, underscoring both the unmet medical need in recurrent pericarditis and the product’s potential for regulatory incentives, including market exclusivity.
Business Significance
Advertisement
From a business perspective, surpassing 50% enrollment represents a key value-inflection and risk-reduction event for Cardiol Therapeutics. Late-stage clinical execution is a major determinant of enterprise value in biopharma, and steady enrollment progress signals operational strength and investigator confidence. Recurrent pericarditis represents a commercially attractive niche market, currently dominated by injectable biologics that are costly and immunosuppressive. CardiolRx™’s oral formulation and differentiated safety profile position it as a potentially broader and more accessible therapy, supporting Cardiol’s long-term commercialization strategy and partnership optionality.
Patients’ Significance
For patients, the progress of the MAVERIC trial is particularly meaningful. Recurrent pericarditis is a painful, debilitating inflammatory condition that can lead to repeated hospitalizations, reduced quality of life, and long-term dependence on corticosteroids or biologic immunosuppressants. These existing therapies often carry significant safety and tolerability burdens. CardiolRx™ aims to offer patients a safer, non-immunosuppressive oral treatment option, potentially enabling earlier intervention in the disease course and reducing reliance on therapies associated with long-term complications.
Policy Significance
At the policy level, MAVERIC aligns with broader healthcare priorities focused on innovation in cardiovascular and inflammatory disease management. Regulatory agencies and health systems increasingly emphasize therapies that can reduce hospitalizations, lower long-term treatment costs, and improve patient quality of life. The development of an oral therapy for recurrent pericarditis supports policy objectives aimed at improving access, adherence, and sustainability of care for rare and underserved patient populations. The trial also contributes to the growing evidence base informing future clinical guidelines and reimbursement decisions in inflammatory heart disease.
The achievement of 50% patient enrollment in the Phase III MAVERIC trial marks a pivotal step forward for Cardiol Therapeutics as it advances CardiolRx™ toward potential regulatory approval. With strong scientific rationale, rigorous trial design, and expanding global clinical participation, MAVERIC underscores the company’s commitment to delivering high-quality, GxP-compliant clinical evidence. As enrollment continues toward full completion expected in 2026, the trial’s progress represents a significant development for patients, regulators, and stakeholders seeking new, differentiated therapies for recurrent pericarditis.
Source: Cardiol Therapeutics Inc press release
